|
Hikma Pharmaceuticals PLC on Thursday said it will be ‘agile’ in its response to the evolving tariff backdrop as it reiterated its full-year outlook. In a trading statement ahead of Thursday’s annual general meeting, the London-based pharmaceutical group said it continues to expect revenue to grow in the range of 4% to 6% and for core operating profit to be between $730 million to $770 million in 2025. In 2024, Hikma reported revenue of $3.13 billion and operating profit of $612 million. Shares in Hikma were down 0.3% at 1,899.00 pence each in London on Thursday. The wider FTSE 100 index is down 0.3%. Hikma, which has operations in Jordan, said is ‘monitoring’ the evolving tariff backdrop and ‘will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook’. Chief Executive Riad Mishlawi said Hikma is ‘well-positioned’, while recognising the broader geo-political challenges. ‘Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success,’ he added Hikma said it is ‘confident’ that its ‘significant and expanding’ US manufacturing footprint, which supplies the majority of US sales, combined with a focus on quality and reliability of supply, ‘position us well and underpin our resilience in the current environment.’ Hikma continues to expect 2025 Injectables revenue to grow in the range of 7% to 9%, Branded business revenue growth of 6% to 7% in constant currency, with revenue at the Generics business seen broadly flat. Hikma said it will announce interim results for the six months ended June 30, on August 7. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
